Another personalized neoantigen long-peptide vaccine led to the expansion of neoepitope-specific CD8 and CD4 T lymphocytes in the primary tumor and metastases of an NSCLC patient with low tumor mutational burden (TMB) (Table 2) [80]. This evidence concerns the gene CD8A and neoplasm.